ITIkko Tomisaki

Ikko Tomisaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ikko Tomisaki has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Naohiro Fujimoto

    Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan

    8 shared publications
  • Akinori Minato

    Department of Urology, School of Medicine University of Occupational and Environmental Health Kitakyushu Japan

    7 shared publications
  • Naohiro Fujimoto

    Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan

    7 shared publications
  • Akinori Minato

    Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan

    6 shared publications
  • Yujiro Nagata

    Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807‑8555, Japan

    5 shared publications
  • Yujiro Nagata

    Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan

    5 shared publications

Latest Publications

  • Open Access

    Sodium–Glucose Cotransporter 2-Mediated Glucose Uptake Contributes to Glycogen Accumulation in Clear Cell Renal Cell Carcinoma: Implications for Clear Cell Morphology and Potential Therapeutic Relevance

    by Yujiro Nagata, Ikko Tomisaki, Takuo Matsukawa, Nguyen Thu Quynh, Yuto Tsubonuma, Yoshihiro Sugita, Aya Nawata, Keiji Kokubu, Ryoko Baba, Hiroyuki Morimoto, et al.

    Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the functional von Hippel–Lindau (VHL) complex and distinctive clear cell morphology associated with intracellular glycogen and lipid accumulation. However, the mechanism underlying glycogen storage remains unclear. This study was conducted to investigate the relationship between SGLT2, a glucose transporter predominantly expressed in proximal tubular epithelial cells; the cell of origin of ccRCC; and clear cell morphology in ccRCC. Using the VHL-null ccRCC cell line KMRC-1, we investigated the effects of the SGLT2 inhibitor dapagliflozin, SGLT2 knockdown, and VHL overexpression on cellular morphology, intracellular glycogen accumulation, and glucose uptake. Immunohistochemical expression of SGLT2, glucose transporter 1, and VHL was evaluated in morphologically heterogeneous ccRCC specimens. Periodic acid–Schiff (PAS) and PAS with diastase staining, together with quantitative image analysis of PAS-stained cells, showed that dapagliflozin treatment, SGLT2 knockdown, and VHL restoration reduced cytoplasmic area and cytoplasmic PAS staining intensity in KMRC-1 cells. In the fluorescent glucose uptake assay, dapagliflozin significantly reduced the fluorescence signal (p < 0.05). In paired intratumoral analyses of six VHL-deficient ccRCC specimens, SGLT2 immunohistochemical scores were significantly higher in clear cell components than in eosinophilic components (p = 0.026), whereas GLUT1 scores did not differ significantly (p = 0.850). These findings suggest that SGLT2-mediated glucose uptake contributes to glycogen accumulation and the glycogen-rich clear cell morphology of VHL-deficient ccRCC. The potential therapeutic relevance of SGLT2 inhibition in ccRCC warrants further investigation.

  • Reduced Uncoupling Protein 1 Expression in Periprostatic Adipose Tissue and Its Association With Higher Prostate Cancer Grade

    by Eiji Kashiwagi, Miho Ushijima, Shohei Ueda, Yuto Tsubonuma, Yui Mizushima, Yoshihiro Sugita, Takuo Matsukawa, Masatoshi Eto, Ikko Tomisaki, Akinori Minato

    Background: Periprostatic adipose tissue (PPAT) is increasingly recognized as a component of the prostate cancer (PCa) microenvironment. However, the role of uncoupling protein 1 (UCP1) in PPAT remains unclear. We investigated the association between PCa grade and UCP1 expression in PPAT. Methods: After institutional review board approval, we collected PPAT and abdominopelvic adipose tissue (APAT) samples from 83 Japanese patients who underwent robot‐assisted radical prostatectomy for clinically localized PCa. UCP1 mRNA expression in PPAT was quantified by RT‐qPCR and normalized to APAT expression (PPAT/APAT ratio). PPAT volume was estimated by computed tomography. Associations with pathological stage and International Society of Urological Pathology (ISUP) grade were evaluated, and logistic regression was performed to identify factors associated with high‐grade disease (ISUP 4/5). Results: In the univariable logistic regression analysis, lower (log‐transformed) UCP1 expression was significantly associated with high‐grade PCa ( ISUP 4/5) (odds ratio [ OR ] 0.415, 95% confidence interval [ CI ] 0.180–0.883, p = 0.027). Age, prostate serum antigen ( PSA ) concentration, and PPAT volume were not significantly associated with high‐grade disease. In the multivariable analysis adjusted for age, PSA concentration, and PPAT volume, UCP1 expression remained independently associated with high‐grade PCa ( OR 0.438, 95% CI 0.188–0.945, p = 0.035). No other clinicopathological variables demonstrated independent associations. Conclusions: Reduced UCP1 expression in PPAT was independently associated with high‐grade PCa. PPAT UCP1 expression may represent a microenvironment‐associated marker reflecting PCa severity.


  • Open Access

    Sodium–Glucose Cotransporter 2 and Glucose Levels Affect Clear Cell Renal Cell Carcinoma Progression

    by Yujiro Nagata, Ikko Tomisaki, Hisami Aono, Nguyen Thu Quynh, Eiji Kashiwagi, Naohiro Fujimoto

    The biological significance of sodium–glucose cotransporter 2 (SGLT2) in clear cell renal cell carcinoma (ccRCC) has yet to be elucidated. In this study, we aimed to determine the role of SGLT2 in ccRCC tumor progression. The human ccRCC line KMRC-1, which contains a von Hippel–Lindau (VHL) gene mutation, was used to assess the effects of the SGLT2 inhibitor (SGLT2i) dapagliflozin on proliferation and migration in media containing different glucose concentrations (25, 12.5, or 5 mM). Dapagliflozin significantly reduced cell proliferation and migration in 25 mM glucose medium. Similarly, SGLT2 knockdown involving short hairpin RNA lentiviral transfection significantly decreased cell viability, migration, and colony formation compared with the control subline in 25 mM glucose medium. Moreover, tumor progression was inhibited in the media with low glucose concentrations. Remarkably, 2 µM dapagliflozin inhibited the progression of ccRCC at concentrations as low as 5 mM (normoglycemic model) glucose medium as well as 25 mM (severe glycemia model) glucose medium. In addition, dapagliflozin treatment significantly enhanced the apoptosis of ccRCC cells. Our findings demonstrate that SGLT2 impacts the progression of ccRCC with the VHL mutation. In light of the above findings, SGLT2is, which exert the dual effects of SGLT2 blockade and glycemic control, may represent a novel therapeutic agent, particularly in patients with ccRCC who suffer from concurrent diabetes mellitus. To the best of our knowledge, this is the first preclinical study demonstrating the impact of SGLT2 inhibition on the progression of ccRCC with the VHL mutation.


  • Open Access

    Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes

    by Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna, Shuji Harada, Hiroomi Matsumoto, Soichiro Akasaka, Yujiro Nagata, Akinori Minato, et al.

    Data on the C‑reactive protein (CRP) flare response in patients with metastatic and unresectable urothelial carcinoma (mUC) are limited. The present study aimed to clarify the clinical significance of the CRP flare response in patients with mUC who received pembrolizumab. Between March 2018 and December 2022, patients with mUC who received pembrolizumab following chemotherapy were retrospectively reviewed. Patients were categorized into three groups based on the early kinetics of CRP: i) Flare‑responders, in which CRP levels increased >2‑fold from baseline (BL) within 1 month after pembrolizumab administration (CRP flare) and decreased to below‑BL levels within 3 months; ii) responders, in which CRP levels decreased ≥30% from baseline within 3 months without CRP flare; and iii) non‑responders, which included the remaining patients. Tumor response, survival and incidence of immune‑related adverse events (AEs) were compared between the groups. Of the 108 eligible patients, 17 (16%), 27 (25%) and 64 (59%) were classified as CRP flare‑responders, CRP responders and CRP non‑responders, respectively. Objective response rate was higher in CRP flare‑responders and CRP responders than in CRP non‑responders. Progression‑free survival and overall survival were longer in CRP flare‑responders and CRP responders than in CRP non‑responders. Among CRP flare‑responders, patients with low BL CRP levels had a better tumor response and survival than patients with high BL CRP levels. Notably, there was no difference in the incidence of immune‑related AEs. In patients with mUC who received pembrolizumab, CRP flare‑responders showed favorable oncological outcomes; therefore, BL CRP levels could predict oncological outcomes in CRP flare‑responders.


  • Open Access

    Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

    by Yujiro Nagata, Akinori Minato, Hisami Aono, Rieko Kimuro, Katsuyoshi Higashijima, Ikko Tomisaki, Kenichi Harada, Hiroshi Miyamoto, Naohiro Fujimoto

    Locally advanced or metastatic urothelial carcinoma is a genomically and molecularly heterogeneous disease associated with various clinical outcomes. We aimed to evaluate the association between the status of p53/FGFR3 expression and the efficacy of enfortumab vedotin (EV) in metastatic urothelial carcinoma. We evaluated the association between p53 (abnormal vs. wild-type) or FGFR3 (high vs. low) expression determined by immunohistochemistry and response to EV in 28 patients with metastatic urothelial carcinoma. Overall, 60.7% showed abnormal p53, and 17.9% had high FGFR3 expression. The rates of objective response to EV were statistically higher in patients with abnormal p53 than in those with wild-type p53 (p = 0.038). Patients with pure urothelial carcinoma (n = 18) and low FGFR3 showed significantly better response to EV than those with high FGFR3. When the statuses of p53 and FGFR3 were combined, abnormal p53/low FGFR3 (vs. wild-type p53/high FGFR3) was strongly associated with favorable outcomes in both the entire cohort (p = 0.002) and in cases of pure urothelial carcinoma only (p = 0.023). Immunohistochemically abnormal p53 tumors were found to respond well to EV, while high FGFR3 tumors had a poorer response. Thus, p53 and FGFR3 are potential biomarkers for predicting response to EV treatment in patients with urothelial carcinoma.


  • Open Access

    Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study

    by Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, et al.

    Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. Hence, this study aimed to assess the oncological outcomes of patients with SUC treated with EV for metastatic disease. We retrospectively evaluated consecutive patients with advanced lower and upper urinary tract cancer who received EV after platinum-based chemotherapy and immune checkpoint blockade therapy at six institutions. The objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between patients with pure urothelial carcinoma (PUC) and those with SUC. We identified 44 and 18 patients with PUC and SUC, respectively. Squamous differentiation was the most common subtype element, followed by glandular differentiation and sarcomatoid subtype. Although patients with SUC had a comparable ORR to those with PUC, the duration of response for SUC was short. Patients with SUC had poorer PFS than those with PUC; however, no significant difference was observed in OS. Multivariate analysis revealed that SUC was significantly associated with shorter PFS. Although the response of metastatic SUC to EV was similar to that of PUC, SUC showed faster progression than PUC.


  • Open Access

    Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor

    by Mirii Harada, Ikko Tomisaki, Shohei Shimajiri, Keisuke Kuretake, Kenichi Harada, Naohiro Fujimoto

    Introduction: Small cell carcinoma (SCC) of the kidney is extremely rare. Although the majority of patients with advanced renal small cell carcinoma were treated with a combination of cisplatin and etoposide, the efficacy was limited. We report the first case with renal small cell carcinoma who received nivolumab and cabozantinib.Case presentation: A 57‐year‐old woman was referred to our hospital with a massive left kidney mass and several bone, lymph nodes, liver, and lung metastases. A left renal mass biopsy made the diagnosis of small cell carcinoma. Nivolumab and cabozantinib were used in combination therapy. The tumors were stable during the treatment for 4 weeks. However, the treatment was halted due to a serious adverse event, immune‐related hemophagocytic lymphohistiocytosis. Although immune‐related hemophagocytic lymphohistiocytosis was resolved with corticosteroids, the patient died 3 months after the initiation of nivolumab and cabozantinib.Conclusion: We reported the first case of renal small cell carcinoma treated with nivolumab and cabozantinib.


  • Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab

    by Ikko Tomisaki, Mirii Harada, Shigeru Sakano, Michikazu Terado, Ryoichi Hamasuna, Shuji Harada, Hiroomi Matsumoto, Soichiro Akasaka, Yujiro Nagata, Akinori Minato, et al.

    Objectives: We clarified the effect of concomitant proton pump inhibitor use on oncological outcomes in patients with advanced urothelial carcinoma treated either with chemotherapy or immune checkpoint inhibitor.Methods: We retrospectively reviewed patients with advanced urothelial carcinoma who received paclitaxel–gemcitabine therapy or pembrolizumab after platinum‐based chemotherapy. The patients were divided into four groups based on the treatment regimen and the concomitant use of proton pump inhibitor. We compared survival outcomes between the groups and determined which factors predicted overall survival.Results: Among the 60 and 75 patients treated with paclitaxel–gemcitabine and pembrolizumab, 15 and 29 used a concomitant proton pump inhibitor. Progression‐free and overall survival was significantly shorter in patients who were administered pembrolizumab with concomitant proton pump inhibitor compared to those without. The use of a concomitant proton pump inhibitor had no effect on survival outcomes in patients who received paclitaxel–gemcitabine therapy. Furthermore, progression‐free and overall survival were significantly shorter in patients treated with paclitaxel–gemcitabine therapy compared to those treated with pembrolizumab among patients without concomitant proton pump inhibitor. In contrast, there was no difference in survival outcomes between the two regimens among patients with concomitant proton pump inhibitor. Concomitant proton pump inhibitor use was associated with poor overall survival only in patients treated with pembrolizumab.Conclusion: The use of a concomitant proton pump inhibitor use had no impact on oncological outcomes in patients with advanced urothelial carcinoma treated with paclitaxel–gemcitabine therapy, different from those treated with pembrolizumab.


  • Open Access

    Effect of Early Postoperative Rehabilitation on Length of Hospital Stay after Robot-assisted Radical Prostatectomy

    by Shuto Higuchi, Ryutaro Matsugaki, Ikko Tomisaki, Kiyohide Fushimi, Shinya Matsuda, Satoru Saeki

    Objectives : This study assessed how early postoperative rehabilitation interventions affected the duration of hospital stay in patients with prostate cancer who had radical prostatectomy with robotic assistance. Methods : From the Japanese Diagnosis Procedure Combination database, we extracted case data for patients discharged between April 2014 and March 2020. Patients were recognized by code C61 from the International Classification of Diseases, 10th Edition. We ran a multilevel linear regression analysis to investigate the impact of early rehabilitation on the duration of hospital stay. Results : There were 2151 participants in the trial. In patients with prostate cancer who had resection utilizing robotic-assisted devices, early rehabilitation was related to a substantial decrease in duration of hospital stay (coefficient, −0.86; 95% CI, −1.64 to −0.07; P=0.032). Conclusions : Early postoperative rehabilitation may contribute to shorter hospital stays in patients with prostate cancer at high risk of both postoperative complications and a decline in their ability to perform activities of daily living.